Press releases | Q-linea

1 Jun, 2023

NOTICE OF EXTRAORDINARY GENERAL MEETING IN Q-LINEA AB (PUBL)

The shareholders in Q-linea AB (publ), reg. no. 556729-0217 (the “Company”) are hereby convened to an extraordinary general meeting on Monday 3 July 2023, at 3 pm in...

1 Jun, 2023

Q-linea resolves on an underwritten rights issue of approximately SEK 263 million

Q-linea AB (publ) (”Q-linea” or the ”Company”) (Nasdaq Stockholm: QLINEA) announces that the Board of Directors has decided to carry out an underwritten new share issue of approximately...

23 May, 2023

Q-linea’s partner Pro-Lab Diagnostics starts its first commercial evaluation in the UK

Q-linea AB (publ) (OMX: QLINEA) today announces that its appointed distributor for UK, Pro-Lab Diagnostic have started their first commercial evaluation at a large regional hospital in the...

22 May, 2023

Q-linea participates in first Italian public tender

Q-linea AB (publ) (OMX: QLINEA) today announces that the company has participated in a public tender in Italy with the ASTar® Instrument and Consumables. “This tender is one...

15 May, 2023

NOTICE OF ANNUAL GENERAL MEETING IN Q-LINEA AB (PUBL)

The shareholders in Q-linea AB (publ), reg. no. 556729-0217 (the “Company”) are hereby convened to the annual general meeting on Tuesday 13 June 2023, at 4 pm in...

10 May, 2023

Q-linea signs distribution agreement for Norway

Q-linea AB (publ) (OMX: QLINEA) today announces that the company has signed an exclusive distribution agreement for Norway with Montebello Diagnostics AS. In line with Q-linea's strategy to...

4 May, 2023

Interim report 1 January–31 March 2023

COMMERCIAL EXPANSION CONTINUING ACCORDING TO PLAN First quarter: 1 January - 31 March Net sales amounted to SEK 0 million (5.8). The operating result totalled SEK -62.2 million...

27 Apr, 2023

Invitation to presentation of Q-linea’s Interim report Q1-2023 on May 4, 2023

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s Interim report for the period January – March 2023 on Thursday 4 May 2023, at 07:30 a.m. (CEST).

24 Apr, 2023

Changed date for the annual general meeting

The board of Q-linea AB (publ) ("Q-linea" or the "Company") has decided to change the date of the annual general meeting. The background to the board's decision is...

24 Apr, 2023

Q-linea initiates cost-saving program

Q-linea AB (publ) (OMX: QLINEA) is today initiating a cost-saving program with the purpose of enabling investment in the updated commercialisation strategy. The cost savings are estimated to...

13 Apr, 2023

Q-linea publish the Annual report for 2022

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), announced today that the Annual Report for the 2022 fiscal year has been published. The Annual Report is attached and can also...

12 Apr, 2023

Q-linea presents at Life Science Investor Konference in Copenhagen – new time

Q-linea is participating in the Life Science Investor Konference on April 19, 2023 at the Symbion, Fruebjervej 3, in Copenhagen. Q-linea’s CEO Jonas Jarvius presents on April 19...

5 Apr, 2023

Q-linea presents at Life Science Investor Konference in Copenhagen

Q-linea is participating in the Life Science Investor Konference on April 19, 2023 at the Symbion, Fruebjervej 3, in Copenhagen. Q-linea’s CEO Jonas Jarvius presents on April 19...

4 Apr, 2023

Q-linea signs distribution partnership for Poland

Q-linea AB (publ) (OMX: QLINEA) today announces that the company has signed a a non-exclusive distribution agreement for Poland with Integra Diagnostic Sp. z.o.o. In alignment with Q-linea's...

3 Apr, 2023

Q-linea receives first ASTar orders under new commercialization strategy

Q-linea AB (publ) (OMX: QLINEA) today announces that the company has received the first two orders for ASTar instruments from Pro-Lab Diagnostics in the UK. The instruments will...

30 Mar, 2023

The proposal by the nomination committee of Q-linea AB (publ) for election of members of the board of directors

The nomination committee of Q-linea AB (publ) submits the following proposals to be presented at the annual general meeting of shareholders to be held on 23 May 2023,...

23 Mar, 2023

Q-linea AB appoints ABG Sundal Collier as liquidity provider

Q-linea AB (publ) (OMX: QLINEA) – Q-linea AB (the “Company”) has appointed ABG Sundal Collier (“ABGSC”) as liquidity provider for the Company’s shares listed on Nasdaq Stockholm. The...

17 Mar, 2023

Q-linea is granted a short-term interest-free loan from the main owner Nexttobe within the framework of the previously communicated loan facility

Q-linea AB (publ) (OMX: QLINEA) – Q-linea announces today that the company's main owner Nexttobe has granted Q-linea a short-term interest-free loan of a total of SEK 57...

16 Mar, 2023

European ASTar clinical impact study receives ethical approval

Q-linea AB (publ) (OMX: QLINEA) – Q-linea today announces that a university hospital in Belgium has received ethical approval to start a clinical impact study using ASTar. The...

28 Feb, 2023

Q-linea presents at Stockholm Corporate Finance 15th Life Science Capital Market Days

Q-linea is participating in the Stockholm Corporate Finance 15th Life Science Capital Markets Days on March 8 - 9, 2023 at the IVA conference center in Stockholm. Q-linea’s...

16 Feb, 2023

Q-linea hires new CFO

Q-linea AB (publ) (OMX: QLINEA) today announces that the company has hired Christer Samuelsson as CFO and IR. Christer Samuelsson takes office on May 1, 2023 when he...

16 Feb, 2023

Year-end report 1 January – 31 December 2022

IMPLEMENTING THE NEW MARKET STRATEGY Fourth quarter: 1 October – 31 December 2022 • Net sales amounted to SEK 0 million (3.9). • The operating result totalled SEK -59.6 million...

16 Feb, 2023

Q-linea updates strategy and is offered updated loan facility

Q-linea AB (publ) (OMX: QLINEA) today announces an updated commercialisation strategy focusing on three key geographies in Europe - UK, Italy and Benelux - through an internal sales...

14 Feb, 2023

Q-linea prepare to start additional testing for US 510(k) application

Q-linea AB (publ) (OMX: QLINEA) today announces that, following feedback from the FDA, the Company will initiate additional testing to verify performance improvements that were implemented after the...

10 Feb, 2023

Q-linea receives IVDR certification

Q-linea AB (publ) (OMX: QLINEA) today announces that the company has received certification according to the new and more comprehensive EU regulation for in-vitro diagnostic medical devices, IVDR

9 Feb, 2023

Invitation to presentation of Q-linea’s Year-end report Q4-2022 on February 16, 2023

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s Year-end report for the period January – December 2022 on Thursday 16 February 2023, at 07:30 a.m. CET.

8 Feb, 2023

Q-linea signs UK distribution partnership

Q-linea AB (publ) (OMX: QLINEA) today announces that the company has signed a distribution partnership for ASTar Instrument and consumables for the UK market with Pro-Lab Diagnostics. Q-linea’s...

19 Jan, 2023

Q-linea strengthens management team

UPPSALA, Sweden, January 19, 2023 – Q-linea today announces that the company has strengthened the management team by including Anders Ljunggren as Manager Project Management Office, PMO. “This...

13 Dec, 2022

Q-linea participates in comparative rapid AST study

Q-linea AB (publ) (OMX: QLINEA) – Q-linea today announces that the company will participate in a study comparing the benefits of three different rapid AST devices to current...

1 Nov, 2022

Q-linea is offered a loan facility of SEK 100 million from main owner Nexttobe

Q-linea AB (publ) (OMX: QLINEA) today announces that the company’s main owner Nexttobe is offering the company SEK 100 million in a loan that can be converted into...

31 Oct, 2022

Interim report 1 January – 30 September 2022

TAKING CONTROL OF OUR FUTURE Third quarter: 1 July – 30 September 2022 • Net sales amounted to SEK 2.9 million (1.1). • The operating result totalled SEK -58.9 million...

27 Oct, 2022

Q-linea’s Q3 interim report will be published on October 31, 2022

Due to yesterday's news that Q-linea is changing the distribution of ASTar, Q-linea will publish the interim report for quarter 3, 2022 earlier than previously announced. It will...

26 Oct, 2022

Q-linea changes ASTar distribution

Q-linea AB (publ) (OMX: QLINEA) today announces that the company has reached an agreement with Thermo Fisher Scientific to end the exclusive global distribution agreement for ASTar instruments...

14 Jul, 2022

Interim report 1 January – 30 June 2022

A MAJOR STEP TOWARDS THE US MARKET Second quarter: 1 April – 30 June 2022Net sales amounted to SEK 4.1 million (4.3).The operating result totalled SEK -73.1 million...

7 Jul, 2022

Invitation to presentation of Q-linea’s Interim report Q2-2022 on July 14, 2022

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s Interim report for the period January – June 2022 on Thursday July 14, 2022 at 07:30 a.m. CEST.

6 Jul, 2022

Q-linea receives letter of intent to evaluate and potential commercialization of Podler

Q-linea AB (publ) (OMX: QLINEA) today announces that the company has received a Letter of Intent (LOI) for the evaluation and a possible commercialization partnership for Podler with...

16 Jun, 2022

Q-lineas publishes digital annual report for 2021

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), announces today that the company's annual report for the financial year 2021 has been published in digital form (xHTML). The digital Annual...

9 Jun, 2022

Q-linea submits US market application to FDA

Q-linea AB (publ) (OMX: QLINEA) today announces that the company has submitted a 510(k) application to the FDA to gain US market authorization. “This is a major milestone...

25 May, 2022

Q-linea achieves CE-mark conformity to IVDR for the ASTar instrument

Q-linea AB (publ) (OMX: QLINEA) today announces that the company has achieved In Vitro Diagnostics Regulation (IVDR) status for the ASTar Instrument. The regulation IVDR ((EU) 2017/746) is...

24 May, 2022

BULLETIN FROM ANNUAL GENERAL MEETING IN Q-LINEA AB (PUBL)

Today on 24 May 2022, Q-linea AB (publ) (the “Company”) held its annual general meeting for the financial year 2021 in Uppsala, whereby the resolutions below were adopted.

5 May, 2022

Interim report 1 January – 31 March 2022

FIRST COMMERCIAL CUSTOMER First quarter: 1 January – 31 March 2022Net sales amounted to SEK 5.8 million (0.0).The operating result totalled SEK -71.8 million (-63.8).The result for the...

28 Apr, 2022

Invitation to presentation of Q-linea’s Interim report Q1-2022 on May 5, 2022

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s Interim report for the period January – March 2022 on Thursday May 5, 2022 at 07:30 a.m. CEST.

25 Apr, 2022

NOTICE OF ANNUAL GENERAL MEETING IN Q-LINEA AB (PUBL)

The shareholders in Q-linea AB (publ), reg. no. 556729-0217 (the “Company”) are hereby convened to the annual general meeting on Tuesday 24 May 2022, at 4 pm in...

22 Apr, 2022

The proposal by the nomination committee of Q-linea AB (publ) for election of members of the board of directors

The nomination committee of Q-linea AB (publ) submits the following proposals to be presented at the annual general meeting of shareholders to be held on 24 May 2022,...

21 Apr, 2022

Q-linea exhibits at ECCMID

Q-linea AB (publ) (OMX: QLINEA) - Q-linea today announces that it will host an exhibit at the most important trade fair, European Congress of Clinical Microbiology & Infectious...

14 Apr, 2022

Q-linea publish the Annual report for 2021

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), announced today that the Annual Report for the 2021 fiscal year has been published. The Annual Report is attached and can also...

8 Apr, 2022

Q-linea’s ASTar classified as a breakthrough device by the FDA

Q-linea AB (publ) (OMX: QLINEA) today announces that ASTar has received a breakthrough device designation by the U.S. Food and Drug Administration (FDA).The categorization “breakthrough device” can...

17 Feb, 2022

Year-end report 1 January – 31 December 2021

THE YEAR ENDS WITH SEVERAL SIGNIFICANT EVENTS Fourth quarter: 1 October–31 December 2021Net sales amounted to SEK 3.9 million (0.0).The operating result totalled SEK -51.6 million (-57.1).The result...

16 Feb, 2022

Excellent clinical results from large commercial evaluation

Q-linea AB (publ) (OMX: QLINEA) - Q-linea today announces the results from the commercial evaluation performed by Thermo Fisher Scientific™ and supported by Q-linea during the summer 2021....

14 Feb, 2022

Invitation to presentation of Q-linea’s Year-end report 2021 on February 17, 2022

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s Year-end report for the period January – December 2021 on Thursday February 17, 2022 at 07:30 a.m. (CET).

11 Jan, 2022

The antibiotics panel in ASTar is expanded to offer even broader coverage

Q-linea AB (publ) (OMX: QLINEA) - Q-linea today announces that the antibiotics panel for the rapid AST system ASTar® for gram-negative bacteria has been updated with several important...

14 Dec, 2021

Q-linea strengthens management team

UPPSALA, Sweden, December 14, 2021 – Q-linea today announces that the company has strengthened the management team by including Victoria Lerneryd and Ulrika Stolpe as Manager Quality Assurance...

1 Dec, 2021

The first patients are included in the US clinical trial for ASTar

Q-linea AB (publ) (OMX: QLINEA) – Q-linea announces today that the US study for ASTar® is entering the final phase and that the first patient samples now have...

4 Nov, 2021

Interim report 1 January – 30 September 2021

Intense launch preparations Third quarter: 1 July – 30 September 2021Net sales amounted to SEK 1.1 million (0.0).The operating result totalled SEK -50.0 million (-50.0).The result for the...

28 Oct, 2021

Invitation to presentation of Q-linea’s Interim report Q3-2021 on November 4, 2021

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s interim report for the period January – September 2021 on Thursday November 4, 2021 at 07:30 a.m. CET.

15 Oct, 2021

Q-linea signs first commercial evaluation contract for ASTar

Q-linea AB (publ) (OMX: QLINEA) – Q-linea announces today that the first commercial evaluation contract has been signed for ASTar® with a Swedish regional hospital. The ASTar Instrument...

7 Oct, 2021

Q-linea’s ASTar launched in Europe

Q-linea AB (publ) (OMX: QLINEA), a diagnostics company focusing on developing and delivering solutions for diagnosing infectious diseases accurately and quickly, today announces that the company's commercial partner...

6 Oct, 2021

Q-linea is taking the next step in the clinical study for the US market

Q-linea AB (publ) (OMX: QLINEA), a diagnostics company focusing on developing and delivering solutions for diagnosing infectious diseases accurately and quickly, today announces that the company has started...

15 Jul, 2021

Commercialisation of ASTar started

Second quarter: 1 April–30 June 2021Net sales amounted to SEK 4.3 million (0.1).The operating result totalled SEK -68.2 million (-58.6).The result for the period amounted to SEK -68.0...

8 Jul, 2021

Invitation to presentation of Q-linea’s Interim report Q2-2021 on July 15, 2021

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s interim report for the period January – June 2021 on Thursday July 15, 2021 at 07:30 a.m. CEST.

30 Jun, 2021

Change in the number of shares and votes in Q-linea AB

Q-linea AB (publ) (”Q-linea” or ”the Company”), today announced that the number of shares and votes in Q-linea has increased during the month of June due to the...

10 Jun, 2021

Q-linea has carried out a directed issue of 2.2 million shares, raising gross proceeds of SEK 301 million

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR THE UNITED STATES OF AMERICA...

10 Jun, 2021

Q-linea announces intention to carry out a directed share issue

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR THE UNITED STATES OF AMERICA...

7 Jun, 2021

Q-linea initiates US 510(k) clinical study for ASTar

Q-linea AB (publ) (OMX: QLINEA), a diagnostics company focused on developing and delivering solutions to diagnose infectious diseases accurately and rapidly, today announced that the company has started...

4 Jun, 2021

Commercial evaluation of the ASTar system in Europe started

Q-linea AB (publ) (OMX: QLINEA), a diagnostics company focused on developing and delivering solutions to diagnose infectious diseases accurately and rapidly, today announces the start of commercial evaluation...

25 May, 2021

BULLETIN FROM ANNUAL GENERAL MEETING IN Q-LINEA AB (PUBL)

Today on 25 May 2021, Q-linea AB (publ) (the “Company”) held its annual general meeting for the financial year 2020 in Uppsala, whereby the resolutions below were adopted.

6 May, 2021

Interim report 1 January – 31 March 2021

An intensive start to 2021 First quarter: 1 January – 31 March 2021Net sales amounted to SEK 0.0 million (0.2).The operating result totalled SEK -63.8 million (-55.9).The result...

4 May, 2021

Q-linea achieves CE-IVD approval for ASTar

Q-linea AB (publ) (OMX: QLINEA) today announces that the company through very good study results has received a CE-IVD mark for the antibiotic susceptibility system ASTar®. Essential Agreement...

29 Apr, 2021

NOTICE OF ANNUAL GENERAL MEETING IN Q-LINEA AB (PUBL) – CORRECTION

Correction - addition of a new item, number 14, on the agenda and addition of the auditor's statement as to whether the annual general meeting’s guidelines for remuneration...

29 Apr, 2021

Invitation to presentation of Q-linea’s Interim report Q1, 2021 on May 6, 2021

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s Interim report for the period January – March 2021 on Thursday, May 6, 2021 at 07:30 (CEST). Q-linea...

26 Apr, 2021

NOTICE OF ANNUAL GENERAL MEETING IN Q-LINEA AB (PUBL)

The shareholders in Q-linea AB (publ) reg. no. 556729–0217 (the “Company”) are hereby convened to the annual general meeting on Tuesday 25 May 2021. In light of the...

26 Apr, 2021

The proposal by the nomination committee of Q-linea AB (publ) for election of members of the board of directors

The nomination committee of Q-linea AB (publ) submits the following proposals to be presented at the annual general meeting of shareholders to be held on 25 May 2021,...

15 Apr, 2021

Q-linea publish the Annual report for 2020

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), announced today that the Annual Report for the 2020 fiscal year has been published. The Annual Report is attached and can also...

31 Mar, 2021

Q-linea presents positive interim data from European trial

Q-linea AB (publ) (OMX: QLINEA) today announced very good interim results from the pivotal European trial for the antibiotic susceptibility system ASTar®. EA was over 94 percent, CA...

16 Mar, 2021

Q-linea signs first site for US study

Q-linea AB (publ) (OMX: QLINEA) today announced that the company has contracted Thermo Fisher Scientific as the first site to participate in the company's US clinical study for...

10 Mar, 2021

Q-linea has received first order on ASTar

Q-linea AB (publ) (OMX:QLINEA), today announced that the company’s global sales partner Thermo Fisher Scientific has placed their first order on ASTar® instruments and consumables. The value of...

18 Feb, 2021

Year-end report 1 January – 31 December 2020

Well prepared ahead of commercialisation Fourth quarter: 1 October - 31 December 2020Net sales amounted to SEK 0.0 million (0.0).The operating result totalled SEK -57.1 million (-62.1).The result...

15 Feb, 2021

Invitation to presentation of Q-linea’s Year-end report 2020 on February 18, 2021

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s Year-end report for the period January – December 2020 on Thursday, February 18, 2021 at 07:30 a.m. CET.

10 Dec, 2020

Q-linea initiates pivotal clinical study for ASTar

Q-linea AB (publ) (OMX:QLINEA), today announced that the company has started the pivotal clinical study for ASTar in Europe. “It feels fantastic to have started the clinical study...

20 Nov, 2020

Jonas Jarvius, CEO of Q-linea presents at Life Science Day

On November 26 at 9.30 (CET) Jonas Jarvius, CEO at Q-linea AB presents the latest developments in the company at Redeye. The presentation is broadcast live and can...

10 Nov, 2020

Q-linea develops portable blood culture technology

Q-linea AB (publ) (OMX: QLINEA), today announced that the company has started the development of a portable blood culture technology with the goal of shortening the time from...

5 Nov, 2020

INTERIM REPORT 1 JANUARY – 30 SEPTEMBER 2020

ASTar has been tested at the Uppsala University Hospital before the start of studiesThird quarter, 1 July – 30 September 2020Net sales amounted to SEK 0.0 million (0.0).The...

29 Oct, 2020

Invitation to presentation of Q-linea’s Interim report Q3-2020 on November 5, 2020

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s interim report for the period January – September 2020 on Thursday, November 5, 2020 at 07:30 a.m. CET.Q-linea...

28 Oct, 2020

Webinar Tuesday November 10th: Equal and better care for everyone

Q-linea AB (publ) (OMX: QLINEA), invites you to a webinar with presentations followed by a Q&A session by CEO Jonas Jarvius, Research Director Mats Gullberg and Marketing &...

11 Sep, 2020

Q-linea enters into an agreement with Hvidovre Hospital as a participant in the clinical study

Q-linea AB (publ) (OMX:QLINEA), today announced that Hvidovre Hospital in Denmark will participate in the company's European pivotal clinical study, which will start in the autumn of 2020. Through...

4 Sep, 2020

Q-linea installs the first ASTar system at Uppsala University Hospital

Q-linea AB (publ) (OMX: QLINEA), today announced that an ASTar® instrument is now being used for beta testing at Uppsala University Hospital and that the hospital will participate...

16 Jul, 2020

INTERIM REPORT 1 JANUARY – 30 JUNE 2020

Strong study results and virtual presentation of ASTar Second quarter, 1 April –30 June 2020 Net sales amounted to SEK 0.1 million (0.5). The operating result totalled SEK -58.6...

9 Jul, 2020

Invitation to presentation of Q-linea’s Interim report Q2-2020 on July 16, 2020

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s interim report for the period January – June 2020 on Thursday, July 16, 2020 at 07:30 a.m. CET....

30 Jun, 2020

Change in the number of shares and votes in Q-linea AB

Q-linea AB (publ) (”Q-linea” or ”the Company”), today announced that the number of shares and votes in Q-linea has increased during the month of June due to the...

2 Jun, 2020

Q-linea has carried out a directed issue of 4 million shares, raising proceeds of SEK 270 million

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR THE UNITED STATES OF AMERICA...

2 Jun, 2020

Q-linea announces intention to carry out a directed share issue

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR THE UNITED STATES OF AMERICA...

26 May, 2020

BULLETIN FROM ANNUAL GENERAL MEETING IN Q-LINEA AB (PUBL)

Q-linea AB (publ) (OMX:QLINEA), Today on 26 May 2020, Q-linea AB (publ) (the “Company”) held its annual general meeting for the financial year 2019 in Uppsala, whereby the...

25 May, 2020

Webinar Friday June 5th: How can we improve infection diagnostics with ASTar

Q-linea AB (publ) (OMX: QLINEA), invites you to a webinar on June 5at 2pm and 7pm CEST with presentations by CEO Jonas Jarvius, Research Director Mats Gullberg...

12 May, 2020

Q-linea announces positive results from prospective study with ASTar

Q-linea AB (publ) (OMX: QLINEA), today announced positive results from a prospective patient study conducted together with Uppsala University Hospital. In the study, the ASTar system analyzed samples...

7 May, 2020

INTERIM REPORT 1 JANUARY – 31 MARCH 2020

Q-linea signs global partnership with Thermo Fisher Scientific for commercialization of ASTarFirst quarter, 1 January –31 March 2020 Net sales amounted to SEK 0.2 million (0.4). The operating result...

29 Apr, 2020

Invitation to presentation of Q-linea’s Interim report Q1-2020 on May 7, 2020

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s interim report for the period January – March 2020 on Thursday, May 7, 2020 at 07:30 a.m. CET....

27 Apr, 2020

NOTICE OF ANNUAL GENERAL MEETING IN Q-LINEA AB (PUBL)

The shareholders in Q-linea AB (publ), reg. no. 556729-0217 (the “Company”) are hereby convened to the annual general meeting on Tuesday 26 May 2020, at 4 pm in...

24 Apr, 2020

The proposal by the nomination committee of Q-linea AB (publ) for election of members of the board of directors

The nomination committee of Q-linea AB (publ) submits the following proposals to be presented at the annual general meeting of shareholders to be held on 26 May 2020,...

17 Apr, 2020

Q-linea publish the Annual report for 2019

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), announced today that the Annual Report for the 2019 fiscal year has been published. The Annual Report is attached and can also...

26 Mar, 2020

Q-linea has solved the component problem

Q-linea AB (publ) (OMX: QLINEA), today announced that the problem discovered in October last year has now been solved. With respect to the component that previously caused a...

13 Feb, 2020

YEAR-END REPORT 1 JANUARY – 31 DECEMBER 2019

Q-linea signs global partnership with Thermo Fisher Scientific for commercialization of ASTar intensifies ahead of ASTar launchFourth quarter, 1 October–31 December 2019 Net sales amounted to SEK 0.0 million...

12 Feb, 2020

Q-linea signs global partnership with Thermo Fisher Scientific for commercialization of ASTar

Q-linea AB (publ) (OMX: QLINEA), today announced that the company has entered into a worldwide exclusive partnership with Thermo Fisher Scientific for the commercialization of ASTar.“We are very...

6 Feb, 2020

Invitation to presentation of Q-linea’s Year End Report Q4-2019 on February 13, 2020

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s Year End Report for the period January – December 2019 on Thursday, February 13, 2020 at 07:30 a.m....

31 Jan, 2020

Change in the number of shares and votes in Q-linea AB

Q-linea AB (publ) (”Q-linea” or ”the Company”), today announced that the number of shares and votes in Q-linea has increased during the month of January due to subscription...

7 Nov, 2019

INTERIM REPORT 1 JANUARY – 30 SEPTEMBER 2019

A quarter of intense preparation Third quarter, 1 July - 30 September 2019 Net sales amounted to SEK 0.0 million (0.3). The operating result totalled SEK -35.8 million (-28.8). The...

31 Oct, 2019

Invitation to presentation of Q-linea’s Interim Report Q3-2019 on November 7, 2019

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s Interim Report for the period January – September 2019 on Thursday, November 7, 2019 at 07:30 a.m. CET....

30 Oct, 2019

Q-linea receives positive response from the FDA for the design of the company’s planned clinical study in the USA

Q-linea AB (publ) (OMX: QLINEA, announced today that the company has received the official response including a number of clarifications and very positive feedback from the US Food...

22 Oct, 2019

Q-linea postpones start of the clinical trials

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), today announced that the clinical trials, in the United States and Europe, for the company's first product ASTar® are expected to begin in the second...

3 Sep, 2019

Q-linea strengthens management team

UPPSALA, Sweden, 3 September, 2019 - Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), a diagnostic company focused on developing and delivering solutions to accurately and rapidly diagnose infectious diseases, today announced Thomas Fritz has been appointed...

31 Jul, 2019